47 results about "Allopurinol" patented technology

The invention discloses a preparation method of an astragalus extract with a uric acid reducing effect, and belongs to the technical field of biological medicines. The method comprises the following steps: concentrating an ethanol extract of radix astragali, extracting by using n-butyl alcohol, ethyl acetate and petroleum ether respectively, and concentrating an extract to obtain n-butyl alcohol, ethyl acetate and petroleum ether extraction parts and residual parts respectively, so as to obtain an n-butyl alcohol extract, namely the radix astragali extract for reducing uric acid. Efficacy experiments show that the normal butanol extraction part of the ethanol extract of the astragalus membranaceus can obviously reduce the serum uric acid level (SUA) of a mouse with hyperuricemia, inhibit the activity of xanthine oxidase (XOD) and effectively improve kidney injury caused by the hyperuricemia. The uric acid reducing effect of the radix astragali n-butyl alcohol extract is close to that of a clinical drug allopurinol, and the radix astragali n-butyl alcohol extract has wide development and application prospects in the aspect of relieving hyperuricemia.

The present disclosure provides methods and drug products for treating CDKL5 deficiency disorder using allopurinol to reduce seizures and improve neurological function by upregulating CDKL5 paralogues and modulating neuronal pathways. The disclosure includes pharmaceutical formulations of allopurinol for standalone or adjunct therapy with anti-epileptic drugs, along with specific dosing regimens. Preclinical and clinical data demonstrate the potential efficacy of allopurinol in reducing treatment-resistant seizures and improving cognitive and motor outcomes in CDKL5 deficiency disorder patients.

The present invention provides a pharmaceutical composition comprising a therapeutically effective amount of allopurinol, febuxostat, or a pharmaceutically acceptable salt thereof as an active ingredient for preventing or treating cardiovascular disease, in which the composition is administered to a subject having a serum uric acid level of 6 mg / dl or higher to reduce the serum uric acid level of the subject to less than 6 mg / dl. Therefore, the pharmaceutical composition according to the present invention exhibits an excellent effect on xanthine oxidase inhibitor and is administered to selected subjects to effectively treat or prevent cardiovascular disease.

The present invention provides a pharmaceutical composition comprising a therapeutically effective amount of allopurinol, febuxostat, or a pharmaceutically acceptable salt thereof as an active ingredient for preventing or treating cardiovascular disease, in which the composition is administered to a subject having a serum uric acid level of 6 mg / dl or higher to reduce the serum uric acid level of the subject to less than 6 mg / dl. Therefore, the pharmaceutical composition according to the present invention exhibits an excellent effect on xanthine oxidase inhibitor and is administered to selected subjects to effectively treat or prevent cardiovascular disease.

The application discloses a tetrapeptide IR4 with uric acid reducing activity, and a preparation method and application thereof, and belongs to the technical field of small molecular peptides. The amino acid sequence of the tetrapeptide IR4 is IDWR, and the tetrapeptide IR4 can be prepared by a solid-phase synthesis method and an enzymatic hydrolysis method. The tetrapeptide IR4 is identified from a porphyra haitanensis protease hydrolysate, has potential interaction with xanthine oxidase, and can reduce the uric acid content of zebrafish by 33.6% (to 5.93+ / -0.47 mu mol / g protein) at a concentration of 100 mu g / mL. Compared with an anserine (which can reduce the uric acid content of zebrafish by 25.7%), the tetrapeptide IR4 has better uric acid reducing activity. Compared with allopurinol (which can reduce the uric acid content of zebrafish to 4.61+ / -1.11 mu mol / g protein), the uric acid reducing ability of the tetrapeptide IR4 and the allopurinol has no significant difference. The tetrapeptide IR4 can be used for preparing uric acid reducing drugs and relieving hyperuricemia.

The invention relates to the technical field of medicines, in particular to a traditional Chinese medicine composition for relieving gout and application thereof. The invention provides a traditional Chinese medicine composition for relieving gout. The traditional Chinese medicine composition comprises the following components in parts by mass: 8-12 parts of an American ginseng extract, 3-6 parts of a poria cocos extract, 6-9 parts of a turmeric extract, 0.8-1.2 parts of a dried ginger extract, 7-13 parts of a cyclocarya paliurus extract, 6-10 parts of a salted cortex phellodendri extract, 4-8 parts of a gynura procumbens extract, 8-12 parts of a nine-processed rhizoma polygonati extract, 8-12 parts of a coix seed extract and 2-6 parts of a corn stigma extract. The traditional Chinese medicine composition can effectively reduce the activity of xanthine oxidase and the content of uric acid in blood, so that gout is relieved, and the effect of the traditional Chinese medicine composition is superior to that of conventionally used western medicine allopurinol.

The invention relates to the technical field of nephritis medicine, in particular to an AAGN disease metabolism marker, a kit and application of the AAGN disease metabolism marker. In the blood or urine metabolism marker, the blood metabolism marker is prepared from one or more of 6-methyl nicotinamide, hypo-sulphosarcosine, guanosine, allopurinol, 8-hydroxy-2 '-deoxyguanosine, triglyceride or lysophosphatidylcholine; the urine metabolism markers comprise one or more of D-malic acid, leucyl-alanyl-valine, N-hydroxymethyl nicotinamide, DL-tribulus terrestris alkali, isoxotrexate, 1, 3-dimethyluric acid, leucyl-leucyl-phenylalanine, alloandrosterone, enterodiphenol and p-coumarin, and the urine metabolism markers comprise one or more of D-malic acid, leucyl-alanyl-valine, N-hydroxymethyl nicotinamide, DL-tribulus terrestris alkali, isoxotrexate, 1, 3-dimethyluric acid, leucyl- The metabolic marker combination and the kit are used for evaluating the disease activity state of a patient suffering from ANCA-related glomerulonephritis (AAGN), and have good repeatability, stability and biological correlation.

The application discloses a pentapeptide IK5 with uric acid reducing activity as well as a preparation method and application thereof, and belongs to the technical field of small molecular peptides. The amino acid sequence of the pentapeptide IK5 is ITGYK, and the pentapeptide IK5 can be prepared by a solid-phase synthesis method and an enzymolysis method. The pentapeptide IK5 is identified from a protease enzymolysis liquid of a fine weak red winged seaweed, has potential interaction with xanthine oxidase, and can reduce the uric acid content of zebrafish by 44.4% (to 5.93+ / -0.47 mu mol / g protein) at a concentration of 100 mu g / mL. Compared with ananeine (which can reduce the uric acid content of zebrafish by 25.7%), the pentapeptide IK5 has better uric acid reducing activity. Compared with allopurinol (which can reduce the uric acid content of zebrafish to 4.61+ / -1.11 mu mol / g protein), the uric acid reducing ability of the pentapeptide IK5 and the allopurinol has no significant difference. The pentapeptide IK5 can be used for preparing uric acid reducing drugs and relieving hyperuricemia.

This invention provides an allopurinol hapten, its preparation method, an artificial antigen, an antibody, and their applications. The structure of the allopurinol hapten is shown below. The allopurinol hapten provided by this invention has a spacer arm of suitable length, which allows the characteristic structure of the target molecule to be far away from the carrier protein, maximizing the exposure of the hapten to the immune system while minimizing recognition of the spacer arm, resulting in better antibody recognition of allopurinol. This invention uses this allopurinol hapten to prepare artificial antigens and antibodies, obtaining allopurinol monoclonal antibodies with high titer, strong specificity, and high affinity. The immunoassay method based on this allopurinol artificial antigen and antibody has high specificity and sensitivity, and no cross-reactivity with allopurinol analogs, enabling rapid qualitative and quantitative detection of allopurinol.

The application discloses application of low-molecular pachyman in preparation of a medicine for simultaneously relieving hyperuricemia and liver and kidney injury, and belongs to the technical field of biological medicine. The application finds through experiments that the low-molecular pachyman has good uric acid lowering effect, and the cytotoxicity result shows that the low-molecular pachyman (0-2000 mu g / mL) has no significant toxicity to liver and kidney cells; meanwhile, the application also finds that the low-molecular pachyman can relieve liver and kidney injury caused by allopurinol and benzbromarone when lowering uric acid. Therefore, the low-molecular pachyman in the application has a good application prospect in relieving hyperuricemia caused by oxypurinol and antagonizing liver and kidney injury caused by drugs.

The utility model relates to the technical field of allopurinol preparation, in particular to a multi-effect evaporation device which comprises a base, evaporation cavities are evenly and fixedly installed on the base, communicating pipes are installed among the three evaporation cavities, a rotating frame is arranged on the base in a sliding mode, evaporation tanks are evenly installed on the rotating frame, and the communicating pipes are communicated with the evaporation tanks. A threaded rod is fixedly installed on the base, a rotating disc is rotatably installed on the rotating frame, a threaded sleeve is rotatably installed on the rotating disc, a motor is fixedly installed on the rotating disc, a gear set is installed between the motor and the threaded sleeve, and the threaded sleeve is meshed with the threaded rod. The motor is started to drive the threaded sleeve to rotate anticlockwise through the gear set, so that the threaded sleeve pulls the rotating frame to slide upwards through the rotating disc, the evaporation tank is separated from the evaporation cavity, then the rotating frame is pushed to rotate, station switching can be rapidly carried out, and raw materials do not need to be transferred among different efficiency levels.

The invention relates to application of a dry memory T cell in preparation of a medicine for treating colorectal cancer pulmonary metastasis, and belongs to the technical field of biological medicine. The invention firstly proves that the capability of differentiating the Tscm cells into effector killer T cells can be effectively improved by knocking out the Erbin genes in the Tscm cells in a mouse body, lung metastasis of colorectal cancer is inhibited, and the treatment effect of CAR-T cells can be enhanced by the Tscm cells with the Erbin genes knocked out. In addition, xanthine is detected for many times in a mouse colorectal cancer lung metastasis focus after the Erbin gene in the Tscm cell is knocked out, hypoxanthine can promote generation of more Tscm cells in the tumor metastasis focus, and the Tscm cells are differentiated to generate killer T cells, so that colorectal cancer lung metastasis is inhibited. The metabolic pathway of hypoxanthine is further studied, it is found that allopurinol can inhibit conversion of hypoxanthine into xanthine and uric acid, and it is found that allopurinol can also inhibit colorectal cancer lung metastasis by injecting allopurinol into a colorectal cancer lung metastasis mouse model.

The invention discloses a method for detecting formamide residues in allopurinol. The method comprises the following steps: S1, preparing a reference substance stock solution; s2, preparing a reference substance solution; s3, preparing a test solution; and S4, detecting. According to the detection method, the dissolvability difference of allopurinol and formamide in different solvents is utilized, a solvent which is easy to dissolve in the formamide and a solvent which is difficult to dissolve in allopurinol are selected, an allopurinol sample is dissolved in a dimethyl sulfoxide solvent at a high concentration, then a small amount of dichloromethane solvent is added, the temperature is reduced, allopurinol is separated out, and the content of allopurinol is detected. And the precipitated allopurinol is removed through centrifugation, and the finally obtained test solution only contains residual formamide to be detected (if any). According to the method, the amount of a target object entering a chromatographic system can be increased, and the interference of too high allopurinol sample concentration on the chromatographic system is reduced, so that the problem of too low sensitivity of a method for detecting the formamide residue in allopurinol is solved. Moreover, helium is selected as carrier gas, so that the detection sensitivity can be further improved.

The invention discloses a method for determining the dissolution rate and the dissolution curve of purinol tablets. The dissolution rate of the allopurinol tablets is detected by high performance liquid chromatography instead of an ultraviolet spectrophotometer method used at present. According to the method, a chromatographic column is used as a silica gel bonded octadecylsilane column, an acid solution-organic phase is used as a mobile phase, and an isocratic elution mode is adopted for detection. According to the method for detecting the dissolution rate and the dissolution curve of the allopurinol tablet through the high performance liquid chromatography, detection can be easily and conveniently completed, specificity is high, accuracy is high, repeatability is good, application and linearity are achieved, and the dissolution rate of the allopurinol tablet and the dissolution amount of the dissolution curve can be efficiently and rapidly detected.

The utility model relates to the technical field of allopurinol preparation, and particularly discloses a micro-channel reactor which is characterized in that a hollow mounting ring is arranged in a glass type reactor body, four shunting check rings are arranged in the hollow mounting ring, and a group of comb-tooth-shaped baffles are arranged in each shunting check ring; a reactant is injected into the glass type reactor body along the feeding base, at an inlet of the glass type reactor body, the reactant encounters multiple layers of shunting check rings, a group of comb-tooth-shaped baffles are installed in each shunting check ring, every two of the four comb-tooth-shaped baffles are distributed in a staggered mode, the reactant is shunted into a plurality of fine streams by the first comb-tooth-shaped baffle, and the fine streams are distributed in a staggered mode by the second comb-tooth-shaped baffle. The directions of the streams are changed in the flowing process, then the streams are re-shunted and disorganized on the second-layer comb-tooth-shaped baffle, then the process is repeated, the shunting process is continuously repeated, and in this way, reactants are in full contact and mixed, and good conditions are created for the reaction of allopurinol.

The present invention belongs to the field of pharmaceutical technology. The present invention provides a nitrogen-containing heterocyclic indole xanthine oxidase inhibitor and its preparation method and application. The nitrogen-containing heterocyclic indole xanthine oxidase inhibitor of the present invention is a compound as shown in general formula I or a pharmaceutically acceptable salt, stereoisomer, isotope-labeled substance, solvate, polymorph or prodrug thereof. The nitrogen-containing heterocyclic indole xanthine oxidase inhibitor of the present invention has good xanthine oxidase inhibitory activity, and the IC values of most specific compounds are as follows: 50 The value can reach the micromolar level, which is superior to the inhibitory activity of the classic anti-gout drug allopurinol. It can effectively inhibit uric acid production and has potential application value in anti-hyperuricemia and gout drugs.

The invention relates to an allopurinol purification process, which belongs to the technical field of allopurinol purification, and comprises the following steps: a) dissolving an allopurinol crude product in an alkaline aqueous solution, and carrying out pressure filtration; b) adding a pH gating buffer agent into the allopurinol sodium salt mother liquor, and accurately and stably clamping the pH value of the system within the range of 8.4-8.6; c) adding a seed crystal-impurity anchoring agent into the system, and performing ultrasonic dispersion; d) performing programmed temperature control cooling and constant-temperature curing on the system to enable the crystals to fully grow; and e) separating out a crystallized product through centrifugal filtration, washing and drying in vacuum to obtain the high-purity allopurinol. According to the method, the ionization constant difference which is usually neglected between a target product and impurities is utilized; the pH value of a crystallization system can be accurately clamped at a preset gating point (such as 8.4-8.6) by introducing a core self-made material pH gating buffering agent, so that a microscopic pKa difference is converted into a macroscopic solubility difference in order of magnitude.

The application discloses a composition with a function of reducing uric acid and a preparation process thereof, which is prepared from the following raw materials in parts by weight: 10-30 parts of chicory, 5-20 parts of gardenia, 5-15 parts of mulberry leaves, 5-15 parts of radix puerariae, 10-20 parts of coix seed, 5-15 parts of poria cocos, and 2-8 parts of licorice root. The application has the beneficial effects that: the seven kinds of medicine and food homologous medicinal materials such as chicory and gardenia are scientifically matched, uric acid is reduced through the double ways of inhibiting xanthine oxidase activity and promoting uric acid excretion, the animal experiment shows that the effect is better than that of the positive drug allopurinol, and the safety is high, and there is no toxic side effect; the preparation process is simple, there is no organic solvent residue, various oral dosage forms can be prepared, and the application is suitable for the auxiliary conditioning of hyperuricemia and gout.

A method of treating a proliferative skin disorder includes treating a patient in need thereof with a topical pharmaceutical formulation including allopurinol or a pharmaceutically acceptable salt thereof and the corresponding formulation are provided. In some embodiments, the topical pharmaceutical formulation slows proliferation of cells involved in the cutaneous cellular proliferative disorder. A method of treating a skin condition includes treating a patient in need thereof with a topical pharmaceutical formulation including allopurinol or a pharmaceutically acceptable salt thereof. A topical formulation may include allopurinol or a pharmaceutically acceptable salt thereof and glutathione or a pharmaceutically acceptable salt thereof.

The utility model discloses a convenient-to-clean reaction device for production of allopurinol, which belongs to the technical field of production of allopurinol and comprises a base, a guide post and a support frame are connected onto the base, a reaction tank is mounted on the base through the support frame, a water tank is mounted on one side of the base, and a water outlet is mounted on the other side of the base. A first motor is installed on the guide column, and an output shaft of the first motor is connected with a threaded rod. According to the reaction device convenient to clean and used for production of the allopurinol, water in a water tank is pumped away by starting a water pump, the water is conveyed into a communicating circular plate through a water conveying pipe and then sprayed to the inner wall of the reaction tank from a spraying head, a second motor rotates a rotating rod, the rotating rod drives a stirring plate to stir water in the reaction tank, and the water in the reaction tank is uniformly stirred; the water starts to flow to wash dirt on the inner wall of the reaction tank, and the scraping plate rotates along with the stirring plate, so that the dirt on the inner wall of the reaction tank is scraped off, and the interior of the reaction tank is kept clean.

The invention belongs to the technical field of desalination and evaporation, and discloses an allopurinol desalination and evaporation device which comprises a falling-film evaporator main body, and further comprises a heat exchange assembly fixedly mounted in the falling-film evaporator main body, and a heat exchange assembly fixedly mounted in the falling-film evaporator main body, and the cleaning assembly is arranged in the heat exchange assembly. The pull rod, the first connecting piece and the elastic membrane are connected, the outer end of the elastic membrane is limited by the first abutting piece and the second abutting piece, the outer diameter value of the elastic membrane is increased, the periphery of the elastic membrane makes contact with the inner wall of the heat exchange tube body, and at the moment, the elastic membrane cannot continue to move downwards; the supporting frame is driven to compress the reset elastic piece so that the supporting frame and the elastic membrane can move downwards along the first guide rod, salt attached to the inner wall of the first guide rod can be cleaned through downward movement of the elastic membrane, and therefore the thickness of the inner wall of the heat exchange pipe body is reduced, heat transfer is guaranteed, and then the allopurinol desalting efficiency is improved.

The invention discloses a traditional Chinese medicine composition for treating hyperuricemia as well as a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from semen hoveniae, radix puerariae, semen phaseoli, raw fructus gardeniae, herba taraxaci, poria cocos and rhizoma dioscoreae. According to the traditional Chinese medicine composition, dissolution of effective components is improved through a combined mode of decocting radix puerariae first and decocting other medicines together, dialectical components are adopted, whole-course intervention of upstream generation inhibition, midstream dissolution and crystallization and downstream excretion promotion on hyperuricemia metabolic disorder can be achieved, and the effect of treating hyperuricemia metabolic disorder can be achieved through physique conditioning, heat clearing and diuresis promoting, spleen strengthening and kidney tonifying, detoxification and turbid descending, collateral dredging and blood stasis dissipating. The blood uric acid level and inflammation balance are successfully recovered to a physiological state, and the action mode is superior to a traditional single uric acid reducing strategy and a traditional Chinese medicine application mode of decocting the whole formula simultaneously. In an animal model, the composition has the effects of remarkably reducing uric acid, regulating inflammation, protecting kidney and improving overall physique, the curative effect of a high-dose group is equivalent to that of a classic uric acid reducing medicine allopurinol, and the composition has more advantages in the aspects of kidney pathological repair and long-term safe conditioning.

The invention discloses pentapeptide IK5 with uric acid reducing activity and a preparation method and application thereof, and belongs to the technical field of small molecule peptide. The amino acid sequence of the pentapeptide IK5 is ITGYK, and the pentapeptide IK5 can be prepared through a solid-phase synthesis method and an enzymolysis method. The pentapeptide IK5 is identified from a solieria tenuissima proteolysis solution, has potential interaction with xanthine oxidase, can reduce the uric acid content of zebra fish by 44.4% (reduced to 5.93 + / -0.47 [mu] mol / g protein) when the concentration is 100 [mu] g / mL, and has better uric acid reducing activity compared with goose carnosine (which can reduce the uric acid content of zebra fish by 25.7%). Compared with allopurinol (the uric acid content of zebra fish can be reduced to 4.61 + / -1.11 [mu] mol / g protein), the pentapeptide IK5 and allopurinol have no significant difference in uric acid reducing capacity, and the pentapeptide IK5 can be used for preparing uric acid reducing drugs and relieving hyperuricemia.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a supramolecular extraction method of ancarnosine, an efficacy-superposed uric acid-reducing product and application. The supramolecular extraction method of the ancarnosine comprises the following steps: firstly, adding water into tuna muscles, and crushing to obtain homogenate; adding alkaline protease and cyclodextrin into the homogenate, then adding special enzyme for aquatic products and flavourzyme, carrying out enzymolysis, adding a catalyst in batches, and carrying out purification, so as to obtain the product. According to the invention, the synergistic effect among the alkaline protease, the special enzyme for aquatic products and the flavourzyme is catalyzed by the catalyst, supramolecular extraction of the carnosine with high bioavailability and high extraction rate is carried out, and the carnosine and other effective components are mixed by using an embedding technology to obtain the embedding product for reducing uric acid. Animal model tests show that the uric acid reducing effect of the traditional Chinese medicine composition is better than that of western medicines including benzbromarone and allopurinol, and the traditional Chinese medicine composition has the advantages of being simple in formula, obvious in curative effect and free of toxic and side effects.

The application discloses a hyperuricemia non-human primate model and a construction method thereof, and belongs to the technical field of experimental animals. The construction method comprises the following steps: using a non-human primate, i.e., a cynomolgus monkey, as a model animal, orally administering potassium oxonate and intravenously injecting myo-inositol, so that the blood uric acid content of the cynomolgus monkey is significantly increased within 0.5-8 hours, and the process can be inhibited by a uric acid-lowering drug allopurinol, and based on this, a hyperuricemia model of a non-human primate can be formed. Compared with a model constructed by using rodents, the hyperuricemia non-human primate model constructed by the application can better simulate the related symptoms and physiological processes of human hyperuricemia, and provides a preclinical effect evaluation tool for the research and development of nutrients and drugs in related fields.

Disclosure is a composite mouse model for simulating the exacerbation of periodontitis by hyperuricemia, as well as the establishment methods and applications thereof. The establishment methods includes: intraperitoneally injecting potassium oxonate into a mouse continuously for 7 days to establish a hyperuricemia model; ligating the maxillary second molar of the mouse with a surgical silk thread to construct a periodontitis model; continuously intraperitoneally injecting potassium oxonate into the mouse for another 7 days (days 8 to 14) to establish a composite mouse model that simulates exacerbation of periodontitis by hyperuricemia; continuously intraperitoneally injecting potassium oxonate for 14 days (days 15 to 28) at a fixed frequency once a day to maintain stability of the hyperuricemia model and constructing a stable hyperuricemia compound periodontitis mouse model; and on the 15th day, intraperitoneally injected allopurinol for 14 days continuously to decrease uric acid.

The present invention provides a pharmaceutical composition comprising as an active ingredient a therapeutically effective amount of allopurinol, febuxostat or a pharmaceutically acceptable salt thereof for the prevention or treatment of chronic kidney disease in a subject having a high serum uric acid concentration, wherein when administered to a subject having a serum uric acid level of 6 mg / dl or more, the pharmaceutical composition reduces the subject's serum uric acid level to less than 6 mg / dl. Therefore, the pharmaceutical composition according to the present invention exhibits an excellent effect on xanthine oxidase inhibitors, and thus can effectively treat or prevent chronic kidney disease by being administered to a selected subject.

The invention belongs to the technical field of biological medicine, and particularly relates to application of cannabidiol and allopurinol in preparation of medicine for preventing and treating hyperuricemia and reducing organ injury. Researches find that when cannabidiol and allopurinol are combined, the effect of synergistically reducing the serum uric acid level and the serum creatinine level can be achieved, and then the effect of synergistically improving the uric acid reduction level or preventing and treating hyperuricemia is achieved; meanwhile, when cannabidiol and allopurinol are combined, the effect of synergistically reducing organ injury caused by hyperuricemia can be achieved.

This invention provides an application of *Lactobacillus plantarum* peptidoglycan in the preparation of uric acid-lowering products, relating to the biomedical field. This *Lactobacillus plantarum* peptidoglycan is derived from *Lactobacillus plantarum* (accession number CGMCC No. 25306). Lactobacillus plantarum Extracted from YC, its chemical structure is A1γ. This plant lactobacillus peptidoglycan can regulate uric acid homeostasis through multiple synergistic mechanisms: inhibiting hepatic XOD activity to reduce uric acid production; bidirectionally regulating renal and intestinal uric acid transport proteins (upregulating ABCG2 / OAT1, downregulating URAT1 / GLUT9) to promote excretion; and exerting systemic anti-inflammatory and hepatoprotective effects. This plant lactobacillus peptidoglycan has a significant uric acid-lowering effect without hepatotoxicity or nephrotoxicity, and its safety is superior to allopurinol. This invention provides a novel core material basis and solution for developing multi-pathway, highly safe uric acid-lowering products.

The invention provides a pharmaceutical composition for reducing uric acid as well as a preparation method, application and a product thereof, and belongs to the field of medicines. The pharmaceutical composition for reducing uric acid is composed of a component A and a component B. The component A is composed of 5 parts of pseudobulbus cremastrae seu pleiones, 30 parts of rhizoma smilacis glabrae, 15 parts of herba taxilli, 15 parts of radix astragali, 15 parts of radix salviae miltiorrhizae, 30 parts of semen coicis and 10 parts of radix gentianae macrophyllae. The component B is a xanthine oxidase inhibitor, and the xanthine oxidase inhibitor is allopurinol or febuxostat. The xanthine oxidase inhibitor and the traditional Chinese medicine components including the pseudobulbus cremastrae seu pleiones, the rhizoma smilacis glabrae, the herba taxilli, the radix astragali seu hedysari, the radix salviae miltiorrhizae, the semen coicis and the radix gentianae macrophyllae act together and cooperate with one another, so that the blood uric acid level can be remarkably reduced, and the traditional Chinese medicine composition can be used for treating hyperuricemia, improving kidney functions and pathology and a basis is provided for clinical medication of combination of the traditional Chinese medicine composition and the xanthine oxidase inhibitor.